View Older Stories View More Recent Stories
-
Bernstein Sees Eli Lilly (LLY) in 'Stronger Position Relative to Peers' Following Trump's Executive Order
-
Trump discusses price gouging of 'fat drugs' in the U.S.
-
Trump says drug prices to be cut by 59%
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Eli Lilly & Co. (LLY) to expand Purdue University collaboration with up to a $250M investment to accelerate pharmaceutical innovation
-
Eli Lilly & Co. (LLY) Announces Leaderhsip Changes
-
Trump to pitch sweeping Medicare drug price plan - Politico
-
Eli Lilly & Co. (LLY) option IV flat
-
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.7% Yield
-
Hims & Hers is due to report after the bell on Monday. Here's what to expect
-
Novo Nordisk shares jump as FDA accepts oral Wegovy application
-
Eli Lilly (LLY) PT Lowered to $1,050 at UBS
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) sell-off 'overdone' on CVS move on Wegovy - Leerink
-
Eli Lilly & Co. (LLY) Misses Q1 EPS by 12c; updates guidance
-
Eli Lilly faces Q1 sales headwinds as incretin gains offset by weakness in other drugs
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.2 puts into quarter results
-
Eli Lilly & Co. (LLY) May 2 weekly 885 straddle priced into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put into quarter results
-
Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk
-
Eli Lilly & Co. (LLY) option implied volatility flat into quarter results
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Goldman Sachs Reiterates Buy Rating on Eli Lilly (LLY)
-
HSBC Downgrades Eli Lilly (LLY) to Reduce
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Bernstein on Eli Lilly (LLY): 'Our Top Pick Still Holds'
-
Cantor Fitzgerald Starts Eli Lilly (LLY) at Overweight
-
BMO Capital: 'Eli Lilly (LLY) Positions Orforglipron for a Global Launch'
-
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put as share price up 15.9%
-
Eli Lilly (LLY) PT Lowered to $900 at BMO Capital
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put as share price up 13%
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly shares jump 12% on positive Phase 3 results for oral diabetes drug
-
Eli Lilly & Co. (LLY) Shares Up 13% on GLP-1 Study Update, Trading 832 Handle
-
Eli Lilly & Co. (LLY) oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
-
Bernstein: 'Eli Lilly (LLY) Keeps Taking Share'
-
Pharma stocks slide after Trump signals tariffs on sector
-
Goldman Sachs Upgrades Eli Lilly (LLY) to Buy
-
BofA: 'Weekly GLP-1 TRx growth in March is trending slightly ahead of February'
-
Trump Admin Drops Biden Medicare Obesity Drug Coverage Proposal - Bloomberg
-
BofA highlights 10 stocks to own for Q2
-
Hims & Hers Health (HIMS) expanding access to personalized weight loss care
-
Hims & Hers Health, Inc. (HIMS) said to sell Lilly's Zepbound
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Wells Fargo Releases Regular Quarterly Update to Tactical Ideas List
-
Stocks expected to have increasing option volume: LLY NVO TEM SPY QQQ
-
Lilly's (LLY) Kisunla Fails To Get Eu Approval In Early Alzheimer's
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.3 puts
-
Organovo (ONVO) Provides Business Update
-
Weighing in on obesity: Catalyst-rich 2025 ahead in a growing competitive landscape

